|
Date:
November 18, 2003
Time:
1200 MT
Title:
Radioimmunotherapy for B-Cell Lymphomas
ACPE# 004-000-03-030-L01
-
Speaker: Jeffrey P. Norenberg, MS, BCNP, Pharm D, FASHP,
FAPhA
-
Assistant Professor, and Chair,
Radiopharmaceutical Sciences
-
College of Pharmacy
-
University of New Mexico Health Sciences Center
Objectives:
1.
Identify the structure and function of monoclonal antibodies
for radioimmunotherapy (RIT) of non-Hodgkin’s lymphoma (NHL).
2.
Identify the components of anti-B1 antibody targeting the CD20
surface antigen.
3.
Describe the crossfire effect of beta radiation used to deliver
cytotoxic doses of radiation to tumor cells.
4.
Understand the critical role of patient-specific dosimetry in
RIT.
5.
Understand the safety and efficacy of RIT in NHL.
6.
Describe the adverse events experienced by patients receiving
RIT for NHL.
7.
Understand the risk of human anti-murine antibody
seroconversion in patients treated with RIT.
8.
Describe the treatment regimen, timeline, and scheduling of
patients receiving RIT for NHL.
9.
Understand institutional models for administering RIT and the
roles of key personnel.
10. Describe
the “Early Release Criteria” that allow for outpatient therapy with
radiopharmaceuticals.
Price: $40
per person
To
register call 1-501-686-6486 or email
SEStanfield@uams.edu.
|
